文献速递认知障碍与痴呆脑血管病

APOE ε2与阿尔茨海默型及血管型认知障碍患者Aβ负荷的关联

Association between APOE ε2 and Aβ burden in patients with Alzheimer- and vascular-type cognitive impairment.
PubMed 文献 · Neurology · 2020-09-14

本研究为横断面研究,纳入310例皮层下血管性认知障碍(SVCI)和999例阿尔茨海默病相关认知障碍(ADCI)患者,用PET评估Aβ负荷。结果显示,在ADCI组中ε2携带者Aβ阳性频率低于ε3纯合子(OR 0.43,95%CI 0.23-0.79),而在SVCI组中ε2携带者Aβ阳性频率更高(OR 2.26,95%CI 1.02-5.01),且ε2携带状态与诊断分组存在交互效应(OR 5.12,95%CI 1.93-13.56)。

要点

  • 在ADCI患者中,APOE ε2携带者Aβ阳性风险低于ε3纯合子。
  • 在SVCI患者中,APOE ε2携带者Aβ阳性风险高于ε3纯合子。
  • ε2携带状态与诊断分组对Aβ阳性存在交互效应。

核心结论

  • APOE ε2在SVCI和ADCI患者中与Aβ沉积的关联不同。
  • 存在一个Aβ阳性的APOE ε2携带者SVCI亚组。

研究设计与样本

  • 横断面研究,纳入310例SVCI患者和999例ADCI患者。
  • 采用PET测量Aβ负荷,用多变量逻辑回归分析APOE基因型或诊断组对Aβ阳性的影响。
  • 采用潜在类别聚类分析方法检查潜在亚组的特征。

主要发现

  • 在ADCI组中,ε2携带者较ε3纯合子Aβ阳性频率更低(OR 0.43,95%CI 0.23-0.79)。
  • 在SVCI组中,ε2携带者较ε3纯合子Aβ阳性频率更高(OR 2.26,95%CI 1.02-5.01)。
  • ε2携带状态与诊断分组对Aβ阳性存在交互效应(OR 5.12,95%CI 1.93-13.56),SVCI组中Aβ阳性ε2携带者多于ADCI组。
  • 识别出Aβ阳性的APOE ε2携带者SVCI亚组和Aβ阳性的APOE ε4携带者ADCI亚组。

临床怎么用

  • 在认知障碍患者中解读APOE ε2时需结合临床诊断分型(SVCI vs ADCI)。
  • SVCI患者若携带APOE ε2,应关注其Aβ阳性可能,必要时行Aβ PET评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the association between APOE genotype and β-amyloid (Aβ) burden, as measured by PET in patients with subcortical vascular cognitive impairment (SVCI) and those with Alzheimer disease-related cognitive impairment (ADCI). METHODS: This was a cross-sectional study of 310 patients with SVCI and 999 with ADCI. To evaluate the effects of APOE genotype or diagnostic group on Aβ positivity, we performed multivariate logistic regression analyses. Further distinctive underlying features of latent subgroups were examined by employing a latent class cluster analysis approach. RESULTS: In comparison with ε3 homozygotes, in the ADCI group, ε2 carriers showed a lower frequency of Aβ positivity (odds ratio [OR] 0.43, 95% confidence interval [CI] 0.23-0.79), while in the SVCI group, ε2 carriers showed a higher frequency of Aβ positivity (OR 2.26, 95% CI 1.02-5.01). In particular, we observed an interaction effect of ε2 carrier status and diagnostic group on Aβ positivity (OR 5.12, 95% CI 1.93-13.56), in that relative to ε3 homozygotes, there were more Aβ-positive ε2 carriers in the SVCI group than in the ADCI group. We also identified latent subgroups of Aβ-positive APOE ε2 carriers with SVCI and Aβ-positive APOE ε4 carriers with ADCI. CONCLUSIONS: Our findings suggest that APOE ε2 is distinctly associated with Aβ deposition in patients with SVCI and those with ADCI. Our findings further suggest that there is a distinctive subgroup of Aβ-positive APOE ε2 carriers with SVCI among patients with cognitive impairment.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lee JS, Lee H, Park S, et al. Association between APOE ε2 and Aβ burden in patients with Alzheimer- and vascular-type cognitive impairment. Neurology. 2020. PMID: 32928967. doi:10.1212/WNL.0000000000010811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。